Genome-Wide Study of Ocular Hypertension in the Personalized

advertisement
Genome-Wide Study of Ocular Hypertension
in the Personalized Medicine Research Project
Below is a flowchart and pseudo code used to select Marshfield’s Ocular Hypertension cohort.
Pseudo code can be found on the following pages. Included is information specific to each reference
identified within the applicable flowchart symbols.
If you have questions regarding any of the information presented on this page, you may contact
either:
Peggy Peissig at [email protected] or call: 715.221.9880
James Linneman at [email protected] or call 715.221.7271
FLOWCHART of Ocular Hypertension Phenotyping Process
(1) PMRP
(2) Any
exclusion
diagnoses?
Yes
Exclude
No
(3) Ocular
HTN Dx
Yes
No
No
(4) Glaucoma
Dx
(10) Within
ophthalmology
Yes
(11) 2 or more
diagnoses
Yes
No
No
Yes
No
(5) IOP
Meds
Yes
No
(6) Glaucoma
Surgery (any)
Yes
Exclude
No
(7) Eye exam
Last 2 years
No
Yes
(8) Age 50 +
at last eye
exam
No
Yes
(9) 1+ Comp
eye exam
(ever)
(12) Dx >=
14 days apart
No
Yes
Control
1
Yes
(13) Age >=
40 years at
earliest Dx
No
Yes
Case
Pseudo code for the “Ocular Hypertension” Phenotype
ID
Step
Description
1
a
-Select all subjects from the PMRP cohort who have:
 Consented
 Did not withdraw from the study
 Include subjects with contact_for_research = ‘N’
 Include subjects where questionnaires have been scanned.
2
a
-Exclude subjects with the following ICD9 codes:
- Childhood Glaucoma 365.14
- Glaucoma associated with ocular trauma 365.65
3
a
-Select subjects with the following diagnoses codes:
-Use diagnoses from 1960 to present.
Diagnoses of Ocular Hypertension
'ICD 9' - = '365.04'
'HICDA 2' - = '375.3'
'HICDA 1' - = '378.909'
4
a
-For subjects having no ocular hypertension diagnoses (see 3a above), select
subjects having none of the following diagnoses codes:
Diagnoses of any glaucoma
'ICD 9' - BETWEEN '365.00' AND '365.03'
'ICD 9' - BETWEEN '365.10' AND '365.13'
'ICD 9' - BETWEEN '365.20' AND '365.9'
'HICDA 2' - BETWEEN '375.0' AND '375.2'
'HICDA 2' - = '375.9'
'HICDA 1' - BETWEEN '375.0' AND '375.9'
'ICDA 8' - ='387.0'
5
a
-For subjects having no glaucoma diagnoses (see 4a above), select subjects having
no intraocular pressure lowering medications where route of administration is
ophthalmic. Intraocular pressure lowering medications:
Where THERAPEUTIC_SPECIFIC_DESC='Miotics/Other Intraoc. Pressure
Reducers' AND DRUG_ROUTE_DESC='Ophthalmic'
(See pages 4-5 for complete list).
6
a
-Select from subjects having none of the following glaucoma type surgery
procedures:
-Surgeries to increase drainage of fluid from eye (for open-angle or chronic closedangle glaucoma):
Trabeculectomy 66170 66172
Tube-shunt surgery (seton glaucoma) 66180 66185
Laser trabeculoplasty 65855
Laser sclerostomy 66710 66711
Other Glaucoma surgeries:
Surgery to prevent closure of the drainage angle:
Surgical iridectomy 66625 66630
Laser iridotomy 66761
2
Pseudo code for the “Ocular Hypertension” Phenotype
ID
Step
6
a
Description
Surgery to decrease the amount of fluid produced in the eye:
Cyclocryopathy 66720
Laser cyclophotocoagulation 66710 66711
Surgery for congenital glaucoma (in children):
Goniotomy 65820
Trabeculectomy 65850
7
a
-Select from subjects having at least one eye exam within the last two years if living
or the last two years prior to date of death if deceased, using CPT codes: 92002,
92004, 92012, 92014, 92018, 92019,
or 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215,
99241, 99242, 99243, 99244, 99245 where provider specialty is Ophthalmology or
Optometry.
8
a
-Select from subjects age 50 years or older at most recent eye exam (within last two
years).
9
a
-Select from subjects having one or more comprehensive type eye exams (ever)
using CPT codes: 92004, 92014,
or 99204, 99205, 99214, 99215, 99244, 99245 where provider specialty is
Ophthalmology or Optometry.
10
a
-Select from subjects having ocular hypertension diagnoses codes given by
ophthalmologist/optometrist within ophthalmology/optometry department(s).
11
a
-Select subjects having two or more ocular hypertension diagnoses (see 3a above);
within ophthalmology/optometry (see 10a above).
12
a
-Select subjects having two or more ocular hypertension diagnoses (see 3a above)
within ophthalmology/optometry (see 10a above), where the earliest and most
recent diagnosis are at least fourteen days apart.
13
a
-Select subjects having two or more ocular hypertension diagnoses (see 3a above)
within ophthalmology/optometry (see 10a above), where the earliest and most
recent diagnosis are at least fourteen days apart (see 12a above), and subjects age at
earliest ocular hypertension diagnosis is 40 years or older.
Site Specific Modifications
Marshfield – Excluding subjects with early Ocular Hypertension (OHT) diagnoses (1999 and earlier) with no
newer diagnoses of OHT, having no glaucoma diagnoses of any type (see 4a above), and having at least two eye
exams (see 7a above) after their most recent OHT diagnosis. Assuming false diagnosis based on validation. 72%
of cases abstracted that met above criteria did not meet our criteria for being considered an OHT case (see
Glaucoma OHT abstraction glossary documentation for OHT criteria met definition). We expect this exclusion
to be specific to Marshfield, given our long history of electronic health records. This reflects how the criteria
for diagnosis of OHT has changed over time in our system, per our ophthalmology expert.
3
Pseudo code for the “Ocular Hypertension” Phenotype
ID
Step
Description
Intraocular pressure lowering medications (where route of administration is ophthalmic):
AHFS_SPECIFIC_CATEGORY_DESC
Alpha-Adrenergic Agonists (Eent)
Alpha-Adrenergic Agonists (Eent)
GENERIC_NAME
BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE
Alpha-Adrenergic Agonists (Eent)
Alpha-Adrenergic Agonists (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Beta-Adrenergic Blocking Agents (Eent)
Carbonic Anhydrase Inhibitors (Eent)
Carbonic Anhydrase Inhibitors (Eent)
Carbonic Anhydrase Inhibitors (Eent)
Carbonic Anhydrase Inhibitors (Eent)
Eent Drugs, Miscellaneous
Eent Drugs, Miscellaneous
Eent Drugs, Miscellaneous
Eent Drugs, Miscellaneous
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE/TIMOLOL
BETAXOLOL HCL
BETAXOLOL HCL
BETAXOLOL HCL
LEVOBUNOLOL HCL
LEVOBUNOLOL HCL
LEVOBUNOLOL HCL
METIPRANOLOL
METIPRANOLOL
TIMOLOL
TIMOLOL MALEATE
TIMOLOL MALEATE
TIMOLOL MALEATE
TIMOLOL MALEATE
TIMOLOL MALEATE/PF
TIMOLOL MALEATE/PF
BRINZOLAMIDE
DORZOLAMIDE HCL
DORZOLAMIDE HCL
DORZOLAMIDE HCL/TIMOLOL
MALEAT
DORZOLAMIDE HCL/TIMOLOL
MALEAT
APRACLONIDINE HCL
APRACLONIDINE HCL
CARTEOLOL HCL
CARTEOLOL HCL
CARBACHOL
CARBACHOL
CARBACHOL
CARBACHOL
DEMECARIUM BROMIDE
ECHOTHIOPHATE IODIDE
PHYSOSTIGMINE SULFATE
Miotics
Miotics
Miotics
Miotics
PHYSOSTIGMINE SULFATE
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
Carbonic Anhydrase Inhibitors (Eent)
4
DRUG_NAME
ALPHAGAN
ALPHAGAN P
BRIMONIDINE
TARTRATE
COMBIGAN
BETAXOLOL HCL
BETOPTIC
BETOPTIC S
AKBETA
BETAGAN
LEVOBUNOLOL HCL
METIPRANOLOL
OPTIPRANOLOL
BETIMOL
ISTALOL
TIMOLOL MALEATE
TIMOPTIC
TIMOPTIC-XE
TIMOPTIC
TIMOPTIC OCUDOSE
AZOPT
DORZOLAMIDE HCL
TRUSOPT
COSOPT
DORZOLAMIDETIMOLOL
APRACLONIDINE HCL
IOPIDINE
CARTEOLOL HCL
OCUPRESS
CARBACHOL
CARBASTORZ
CARBOPTIC
ISOPTO CARBACHOL
HUMORSOL
PHOSPHOLINE IODIDE
ESERINE SULFATE
PHYSOSTIGMINE
SULFATE
ADSORBOCARPINE
AKARPINE
ALMOCARPINE
Pseudo code for the “Ocular Hypertension” Phenotype
ID
Step
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Miotics
Prostaglandin Analogs
Prostaglandin Analogs
Prostaglandin Analogs
Prostaglandin Analogs
Prostaglandin Analogs
Prostaglandin Analogs
Description
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL
PILOCARPINE HCL/EPI BIT
PILOCARPINE HCL/EPI BIT
PILOCARPINE HCL/EPI BIT
PILOCARPINE HCL/EPI BIT
PILOCARPINE HCL/EPI BIT
PILOCARPINE HCL/EPI BIT
PILOCARPINE HCL/EPI BIT
PILOCARPINE HCL/EPI BIT
PILOCARPINE HCL/EPI BIT
PILOCARPINE HCL/EPI BIT
PILOCARPINE NITRATE
PILOCARPINE NITRATE
BIMATOPROST
LATANOPROST
LATANOPROST
TRAVOPROST
TRAVOPROST (BENZALKONIUM)
UNOPROSTONE ISOPROPYL
Last updated: April 25, 2012
5
INFA-KARPINE
I-PILOPINE
ISOPTO CARPINE
OCUSERT PILO-20
OCUSERT PILO-40
PILOCAR
PILOCARPINE HCL
PILOKAIR
PILOMIOTIN
PILOPINE HS
PILOPTIC-1
PILOPTIC-2
PILOPTIC-3
PILOPTIC-4
PILOPTIC-6
PILOSOL
PILOSTAT
SPECTRO-PILO
STORZINE 1
STORZINE 2
STORZINE 4
E-PILO-1
E-PILO-2
E-PILO-3
E-PILO-4
E-PILO-6
P1E1
P2E1
P3E1
P4E1
P6E1
PILAGAN
PV CARPINE
LUMIGAN
LATANOPROST
XALATAN
TRAVATAN Z
TRAVATAN
RESCULA
Download